Biogen and the desperation of a need for Alzheimer's drugs

Biogen is set to provoke an early pointer of the direction the FDA will take under new Commissioner Stephen Hahn. Having made the shock decision to resurrect aducanumab after it failed a phase 3 futility analysis, Biogen is set to file for FDA approval of the Alzheimer’s disease drug next year.